Glaukos Corp (GKOS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Glaukos Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 16 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 166.70 $ — 98% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 21.5% passed
- More than 10% revenue growth is expected for the coming year 26.2% passed
- Share count grows by less than 3% a year 6.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 21.7% failed
- Gross margin at 40% or higher and without meaningful erosion 77.5% passed
- Goodwill from acquisitions does not grow faster than revenue 7.5% passed
- Net debt below twice EBITDA 139 m net cash passed
- Operating cash flow covers the profits of the last three years 303 m failed
- Return on capital at 15% or higher, or up versus two years ago -11.0% failed
- Insiders hold at least 10% or are net buyers 3.6% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 16.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 15
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.29 | -0.66 – -0.09 | 691 | 67.7% | 13 |
| 12/31/2027 | 0.50 | 0.04 – 1.04 | 842 | 272.9% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.60 | – | 106 | 28.10 | -31.80 | 1 | -1 |
| 2025: Q1 | -0.32 | – | 107 | 24.60 | -17.00 | -19 | -21 |
| 2025: Q2 | -0.34 | – | 124 | 29.70 | -15.80 | 7 | 6 |
| 2025: Q3 | -0.28 | – | 134 | 38.10 | -12.20 | -10 | -12 |
| 2025: Q4 | -2.32 | – | 143 | 35.70 | -93.40 | 7 | 4 |
| 2026: Q1 | -0.34 | – | 151 | 41.20 | -13.10 | -13 | -17 |
| 2026: Q2 | -0.31 | 8.80 | 186 | 49.60 | -9.90 | 15 | 12 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 114 | 4 | 5 | 0.12 | 12 | 117 | 134 |
| 2017 | 159 | -2 | 0 | 0.00 | 26 | 138 | 166 |
| 2018 | 181 | -13 | -13 | -0.37 | 19 | 174 | 207 |
| 2019 | 237 | -50 | 15 | 0.37 | 0 | 673 | 818 |
| 2020 | 225 | -124 | -120 | -2.70 | -23 | 667 | 1,006 |
| 2021 | 294 | -33 | -50 | -1.07 | 25 | 587 | 1,129 |
| 2022 | 283 | -82 | -99 | -2.09 | -33 | 530 | 1,074 |
| 2023 | 315 | -129 | -135 | -2.78 | -58 | 462 | 940 |
| 2024 | 383 | -122 | -146 | -2.77 | -61 | 767 | 975 |
| 2025 | 507 | -87 | -188 | -3.28 | -46 | 656 | 893 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Glaukos Corporation, ein augenheilkundliches Pharma- und Medizintechnikunternehmen, entwickelt Therapien zur Behandlung von Glaukom, Hornhauterkrankungen und Netzhauterkrankungen in den USA und international. Es bietet die iStent- und iStent-inject-W-Mikro-Bypass-Stents zur Behandlung leichter bis…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 1,094 |
| Headquarters | Aliso Viejo, CA |
| Address | One Glaukos Way, 92656 Aliso Viejo, United States |
| Phone | 949 367 9600 |
| Website | glaukos.com |
| IPO Date | 25. Jun 2015 |
| ISIN | US3773221029 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Thomas William Burns | Chairman & CEO | 1961 |
| Joseph E. Gilliam | President & COO | 1976 |
| Alex R. Thurman | Senior VP & CFO | 1970 |
| Tomas Navratil Ph.D. | Chief Development Officer | 1977 |
| Christopher William Lewis | Vice President of Investor Relations & Corporate Affairs | – |
| Robert L. Davis J.D. | Senior VP, General Counsel & Business Development | 1966 |
| Diana A. Scherer | VP of Compliance & Deputy General Counsel | – |
| Michele M. Allegretto | Senior Vice President of Human Resources | – |
| L. Jay Katz FACS, M.D. | Chief Medical Officer | – |
| Tracy M. Founds | Senior Vice President of Global Quality & Medical Safety | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 16. Jul 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Sell | 10,000 | 160.00 | 1,600,000 |
| 16. Jul 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Other | 10,000 | 38.68 | 386,800 |
| 9. Jul 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Sell | 10,000 | 155.00 | 1,550,000 |
| 9. Jul 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Other | 10,000 | 38.68 | 386,800 |
| 6. Jul 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Sell | 10,000 | 150.00 | 1,500,000 |
| 6. Jul 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Other | 10,000 | 38.68 | 386,800 |
| 1. Jul 2026 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Sell | 716 | 139.06 | 99,567 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.